4.7 Article

Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient

期刊

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01872-19

关键词

ESBL-producing Klebsiella pneumoniae; XDR Pseudomonas aeruginosa; cefiderocol; chronic osteomyelitis; pediatric

资金

  1. NIH/NIAID [K08 AI135093, R01 AI134637, R21 AI143229, K24 AI121296]
  2. UTHealth Presidential Award
  3. University of Texas System STARS Award
  4. Texas Medical Center Health Policy Institute Funding Program
  5. Merck, Inc.
  6. MeMed Diagnostics
  7. Merck
  8. Entasis Therapeutics pharmaceuticals
  9. Entasis Therapeutics

向作者/读者索取更多资源

We report a 15 year-old Nigerian adolescent male with chronic osteomyelitis caused by an extensively drug-resistant (XDR) Pseudomonas aeruginosa strain of sequence type 773 (ST773) carrying bla(NDM-1) and an extended spectrum beta-lactamase (ESBL)-producing Klebsiella pneurnoniae strain. The patient developed neurological side effects in the form of circumoral paresthesia with polymyxin B and asymptomatic elevation of transaminases with aztreonam (used in combination with ceftazidime-avibactam). Cefiderocol treatment for 14 weeks plus bone implantation resulted in apparent cure and avoided amputation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据